• Home »
  • Africa Healthcare »
  • Novartis convenes 13th annual malaria expert panel with a focus on access to quality antimalarials across Africa
Novartis convenes 13th annual malaria expert panel with a focus on access to quality antimalarials across Africa

Novartis convenes 13th annual malaria expert panel with a focus on access to quality antimalarials across Africa

Press Release:

DAR ES SALAAM, Tanzania, June 25, 2014/ -- Malaria experts from countries across Africa are meeting today at the 13th annual National Malaria Control Program (NMCP) Best Practice Sharing Workshop. The gathering provides a platform to discuss and share knowledge and experiences, and to drive dialogue around improved health outcomes and access to quality antimalarial treatments for patients in Africa. For these workshops, Novartis (http://www.novartis.com) works in collaboration with the Global Fund, World Health Organization, the WorldWide Antimalarial Resistance Network, the Kenya Medical Research Institute-Wellcome Trust, Swiss Tropical and Public Health Institute, US Pharmacopeia, Populations Services International, Ifakara Health Institute, and the Pharmacy and Poisons Board.

“These NMCP meetings have led to groundbreaking projects such as the development of SMS for Life to improve antimalarial stock management in rural health facilities,” said Dr. Linus Igwemezie, Head of the Novartis Malaria Initiative (http://www.malaria.novartis.com). “We believe that by bringing together the best minds and leaders in the field, we can help foster new approaches that will help us ensure all patients have access to quality antimalarials and bring us closer to malaria elimination.”

 The successful treatment of malaria depends on the public being informed about the risks of the disease, the importance of sleeping under insecticide treated bednets, and having access to health services including appropriate diagnostic tests and quality-assured antimalarial treatments.(3/page v) Unfortunately, in some countries bednet utilization remains a challenge;(3/page ix) while sub-standard antimalarials (3/page 9) and oral artemisinin monotherapies (3/page xii) remain available, primarily through the private sector. These treatments may contain too little or no active ingredient, thereby putting patients’ lives at risk. (4/pages 22&49)

We suggest you read  Uganda:Surrey hospital surgeons to train Ugandan medical staff

Speaking on behalf of the WorldWide Antimalarial Resistance Network, Dr. Ambrose Talisuna says: “It’s crucial that governments take urgent action to ensure patients are not put at risk of sub-standard treatments. We must make sure that the public is made aware of the importance of taking preventative measures as well. The ongoing role of Novartis in facilitating these workshops provides a platform for discussing these important issues, for sharing best practice in public education and for mapping the sources of poor quality antimalarials.”

NMCP Best Practice Sharing Workshops

Since the first workshop in 2006, groundbreaking projects have emerged such as the SMS for Life program to support more efficient stock management in rural health facilities.  Another key advance was the development of Coartem® Dispersible, the first Artemisinin-based Combination Therapy (ACT) specifically tailored to infants and children, meeting the World Health Organization requirements for a pediatric antimalarial medicine and which was developed in collaboration with Medicines for Malaria Venture.


Distributed by APO (African Press Organization) on behalf of Novartis AG.



Novartis Media Relations


Central media line : +41 61 324 2200

Dermot Doherty

Novartis Global Media Relations

+41 61 696 8653 (direct)

+41 79 536 9755 (mobile)


Nadine Schecker

Novartis Malaria Initiative Communications

+41 61 696 86 33 (direct)

+41 79 682 13 26 (mobile)



e-mail: media.relations@novartis.com


For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis

For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.


Notes to editors


About the Novartis Malaria Initiative

We suggest you read  IBM Watson to boost Africa Healthcare

The Novartis Malaria Initiative (http://www.malaria.novartis.com) is one of the largest access-to-medicine programs in the healthcare industry. Moving forward, Novartis is committed to working towards malaria elimination by driving the development of next-generation antimalarials, with two new classes of drugs currently in clinical development. The most advanced compound is in Phase II clinical trials. For more information, please visit:http://www.malaria.novartis.com